Citations
K. Bjornevik et al. CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis. Science Translational Medicine. 2026. doi: 10.1126/scitranslmed.adz6566
N. Wick et al. Clinical relevance of circulating blood microaggregates and reactivation of Epstein Barr Virus in long-term Post-CoVID syndrome patients. Scientific Reports. 2026. doi: 10.1038/s41598-026-42952-8
J. Stewart and B. Damania. Withaferin A inhibits EBV-driven lymphomagenesis through multiple mechanisms, including EBNA1 degradation. Blood. 2026. doi: 10.1182/blood.2025029771
F.M. Lum et al. Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis. Proceedings of the National Academy of Sciences. 2026. doi: 10.1073/pnas.2519445123
S. Younis et al. EBV reprograms autoreactive anti-CNS B cells as antigen presenting cells in multiple sclerosis. bioRxiv. 2026. doi: 10.64898/2026.02.11.701910
S.S. Nyeo et al. Population-scale sequencing resolves determinants of persistent EBV DNA. Nature. 2026. doi: 10.1038/s41586-025-10020-2
Y. Yasumizu et al. A genetically driven immunologic mechanism underlying the link between EBV and multiple sclerosis. medRxiv. 2026. doi: 10.64898/2025.12.11.25342083
G. Khan and M.J. Hashim. Epidemiology of multiple sclerosis: global, regional, national and sub-national-level estimates and future projections. Journal of Epidemiology and Global Health. 2025. doi: 10.1007/s44197-025-00353-6
N. Sattarnezhad et al. Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls. Proceedings of the National Academy of Sciences. 2025. doi: 10.1073/pnas.2424986122
A. Vojdani et al. Autoimmune responses to myelin-associated proteins as diagnostic and prognostic biomarkers of relapsing-remitting multiple sclerosis: Associations with human herpesvirus-6 and Epstein-Barr virus reactivation. Journal of Advanced Research. 2025. doi: 10.1016/j.jare.2025.02.021
W.H. Robinson et al. Epstein–Barr virus as a potentiator of autoimmune diseases. Nature Reviews Rheumatology. 2024. doi: 10.1038/s41584-024-01167-9
Y. Wong et al. Estimating the global burden of Epstein–Barr virus-related cancers. Journal of Cancer Research and Clinical Oncology. 2022. doi: 10.1007/s00432-021-03824-y
K. Bjornevik et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022. doi: 10.1126/science.abj8222
T.V. Lanz et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022. doi: 10.1038/s41586-022-04432-7
X. Cui and C.M. Snapper. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Frontiers in Immunology. 2021. doi: 10.3389/fimmu.2021.734471
H.H. Balfour, S.K. Dunmire and K.A. Hogquist. Infectious mononucleosis. Clinical & Translational Immunology. 2015. doi: 10.1038/cti.2015.1
E.M. Sokal et al. Recombinant GP350 vaccine for infectious mononucleosis: a phase 2, randomized, double‐blind, placebo‐controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein‐Barr virus vaccine in healthy young adults. The Journal of Infectious Diseases. 2007. doi: 10.1086/523813
M. Epstein, B. Achong and Y. Barr. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. The Lancet. 1964. doi: 10.1016/S0140-6736(64)91524-7
Read the full article here
